空腹時血糖に及ぼすシベンジリン及びジソピラミド投与の影響

概要

論文の詳細を見る
Hypoglycemia has been reported to occur in some patients undergoing treatment with such class la antiarrhythmic drugs as cibenzoline and disopyramide. The changes in the fasting blood sugar (FBS) levels were surveyed in 251 outpatients before and after treatment with cibenzoline and in 416 outpatients before and after treatment with disopyramide at the National Cardiovascular Center from October to November 1996. The FBS before and after treatment with cibenzoline in 43 patients and with disopyramide in 42 patients were thus retrospectively analyzed. Cibenzoline treatment significantly reduced the FBS level (from 98.6±14.2 to 92.1±17.0 mg/dl, p< 0.05), whereas disopyramide treatment did not significantly change the FBS level. Furthermore, in patients receiving cibenzoline treatment, a significant reduction of the FBS was also observed in elderly patients (>65 years), in patients receiving high doses (>300 mg/day), and in patients with a reduced renal function (BUN : >20 mg/dl or Scr : M>1.3, F>1.0 mg/dl). These results suggest that close attention should thus be paid to the occurrence of cibenzoline-induced hypoglycemia in eiderly patients, those receiving high doses and those with a reduced renal function.
1998-10-10